The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Exactly SCHeckler
I'm sure that we've all held shares in companies where BOD's enthusiasm and PR outweighed the reality and share performance in some cases very painfully so.
SAR especially TIM & co have always been understated and have copped a fair bit of criticism on this board for lack of PR etc. They've always been perceived as conservative dour scientists as a pose to "snake oil salesmen" of some un named AIM stocks.
The fact that they are getting excited can't be a coincidence.
We've had a very positive start to 2023 after a let's be honest horrific 2022.
We'll no doubt see more ups and downs this year, but for me IA it should be a vintage year.
KR
ZA
The last sentence for the response to the question below piqued my interest. Certainly not unreasonable to hope for £1 or more to be added to SARS share price if and when we get positive news.
Q20: When do you expect to receive the clinical study report/data pack for sar737 and how long do you expect your evaluation of these reports to take before going forward with the project? Have you/Cruk received any interest for sar737 from any other company/interested party? Just to be clear, have Sarum or cruk received any interest from any parties with respect to progressing sar737?
The process as we understand it is that following the formal termination date, in early January 2023, GSK/Sierra will return all the data "without undue delay" - likely to be a few weeks to receive it and a few weeks to review.
At this stage, we don't know how much interpretation of the data has already been competed by Sierra. If they have generated a report identifying genetic markers with patients who have responded to treatment, that would be very useful.
We have received a number of enquires from potential partners interested in progressing SRA737
KR
ZA
Cambridge, UK, 16 December 2022 - Sareum Holdings plc (AIM: SAR), a biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer , held its Annual General Meeting ("AGM") today and all resolutions were duly passed. Details of the voting results are shown in the table below.
Ordinary Resolutions
Votes For
%
Votes Against
%
Votes Total
% of ISC Voted
Votes Withheld
1. Receive and adopt Report of the Directors and financial statements for the year
6,255,275
99.82
11,023
0.18
6,270,831
9.21
4,533
2. Receive and adopt Renumeration Committee report for the year
5,232,943
85.28
902,951
14.72
6,270,831
9.21
134,937
3. Re-elect Dr John Reader as Director of the Company
6,085,556
98.87
69,338
1.13
6,270,831
9.21
115,937
4. Appoint Shipleys LLP as auditor
5,618,405
91.55
518,753
8.45
6,270,831
9.21
133,673
5. Directors' authority to allot new shares
5,345,322
86.08
864,630
13.92
6,270,831
9.21
60,879
Special Resolution
6. Directors' authority to allot equity securities for cash
5,316,094
85.61
893,858
14.39
6,270,831
9.21
60,879
KR
ZA
RNS
https://www.londonstockexchange.com/news-article/SAR/agm-statement/15760979
KR
ZA
I can't fail but agree with Warty.
All this back and forth, sniping and *****ing isn't really achieving anything.
Most of us know each others positions on SAR.
My position is still as it was on a free trade, still hold far too many shares for my liking.
It definitely hasn't been fun to see a significant (for me) 6 figure drop in my remaining holding on paper.
AGM should be a catalyst one way or another, but we can't control the unknown.
KR
ZA
Thommo
Wouldn't the entrance of one or more of our compounds be transformational to the share price and by default market cap. We'd have no trouble raising funds to aid further clinical development if this was the case.
This would be a dilution I would vote for and participate in if allowed.
KR
ZA
Good find Krone
The CPF and all other partners would undoubtedly have been prepared for this scenario over the significant period of time the Sierra appeared to be de-prioritising SRA 737.
Let's hope any potential talks are already at a late stage.
KR
ZA